Neuroimmune Dysfunction in Alcohol Use Disorder
Completed · Phase 1 · Has a placebo group
Conditions studied: Alcohol Drinking, Alcohol-Related Disorders, Disease, Inflammation, Alcoholism, Cognitive Dysfunction, Pathologic Processes, Drinking Behavior, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Cognition Disorder, Neurocognitive Disorders, Minocycline, Anti-Bacterial Agents, Anti-Infective Agents
In brief
The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.
Key facts
- Study ID
- NCT04210713
- Run by
- University of Maryland, Baltimore
- People needed
- 142
- Starts
- 2020-02-03
- Expected to finish
- 2023-09-20
- Last updated by the study team
- 2023-12-01
Who can join
Age: 25 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP) — Catonsville, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.